Supplemental Materials - Device-based physical therapies in chronic pruritus
收藏NIAID Data Ecosystem2026-05-02 收录
官方服务：
资源简介：
Supplemental information for the Figure 1
应用场景：
创建时间：
2024-06-24
相关数据集
Systematic review on antipruritic therapies for patients with Epidermolysis bullosa
Itch is one of the most burdensome symptoms in epidermolysis bullosa (EB), indicating a hitherto unmet therapeutic need. This review leverages existing data on efficacy of itch treatment in EB to supp
DataCite Commons2024-12-16 更新150
North America Pruritus Therapeutics Market
The North America Pruritus Therapeutics market report offers a thorough competitive analysis, mapping key players’ strategies, market share, and business models. It provides insights into competitor d
IMR REPORTS40
Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence
Nemolizumab, an anti-IL-31 receptor A antibody, is licensed for atopic dermatitis and prurigo nodularis; its role in other chronic pruritus (CP) syndromes is uncertain. To synthesize efficacy, safety
NIAID Data Ecosystem30
Supplementary Material for: Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post-hoc Analysis of KALM-1 and KALM-2
Black and African American (AA) people are over-represented in the kidney failure population; therefore, the safety and efficacy of difelikefalin in Black/AA patients was evaluated. This was a post ho
DataCite Commons2024-01-22 更新70
Supplemental Material related to "Phase 2 randomized controlled trial of serlopitant, a neurokinin 1 receptor antagonist for chronic pruritus in epidermolysis bullosa. U Okata-Karigane et al., 2022"
Supplemental Material related to "Phase 2 randomized controlled trial of serlopitant, a neurokinin 1 receptor antagonist for chronic pruritus in epidermolysis bullosa. U Okata-Karigane et al., 2022"
NIAID Data Ecosystem40
